Table 2.
Interferon-γ (INF-γ) production by IL-2-activated TIL in patients with carcinomatous pericarditis
| IFN-γ production (pg/ml) | HLA class-I | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Histology | Stimulator (cell line) | Origin | Case 1 | Case 2 | Case 3 | Case 4 | A | B | Cw |
| Autologous tumor cells | Malignant pericardial effusion | 325 | 609 | 258 | 221 | ||||
| Squamous cell carcinoma | KE-4 | Esophagus | 356 | <5 | 286 | 16 | 2402/2601 | 4001/5102 | 0101/030 |
| KE-3 | Esophagus | 7 | <5 | 29 | <5 | 0206/2402 | 15/53 | 0401/150 | |
| TE-9 | Esophagus | 12 | 20 | <5 | <5 | 3302/- | 1503/- | ||
| TE-10 | Esophagus | 32 | <5 | <5 | 14 | 2/2402 | 51/55 | 0302/010 | |
| Kuma-1 | Head and neck | 199 | 38 | 261 | 10 | 2603/3302 | 1501/44031 | 0303/140 | |
| RERF-LC-A1 | Lung | <5 | <5 | 12 | ND | 2402/- | 5201/- | 1202/- | |
| LC-1 sq | Lung | 7 | <5 | 31 | <5 | 11/2402 | 44031/- | 1203/160 | |
| Adenocarcinoma | A549 | A549 | Lung 21 | 12 | <5 | <5 | 2602/3001 | 1801/44031 | 1203/160 |
| 1–87 | Lung | <5 | <5 | 38 | ND | 0207/1101 | 4601/5401 | 0102/- | |
| 11–18 | Lung | 7 | 171 | <5 | 190 | 0201/2402 | 5201/5401 | 0102/120 | |
| LC-1 | Lung | <5 | <5 | ND | 14 | 3101/3302 | 1511/44031 | 0303/140 | |
| PC-9 | Lung | 67 | 621 | 22 | 209 | 0206/2402 | 0702/5502 | 0303/070 | |
| MKN-28 | Stomach | <5 | <5 | <5 | <5 | 3101/- | 5101/- | 0304/- | |
| COLO-201 | Colon | <5 | 21 | <5 | 40 | 0101/0201 | 0702/0801 | 0701/070 | |
| Panc-1 | Pancreas | <5 | <5 | <5 | <5 | 0201/1101 | 3801/- | 1203/- | |
| Leukemia | K562 | Erythroblast | 25 | 50 | 31 | 20 | |||
IL-2-activated TIL (5x105 cells) were incubated with the stimulators (1x105 cells) for 18 h, and the INF-γ activity in the supernatant was measured using an ELISA kit
ND not determined